Home The Action General

Mon,24Nov2014

General

The biological and medical importance of the endogenously generated gaseous transmitter nitric oxide was recognized by the 1998 Nobel Prize for Medicine/Physiology. It is now clear that several “gasotransmitters” exist and this class of mediators also includes carbon monoxide (CO) and hydrogen sulfide (H2S). Several of the groups leading this research field are based in Europe, thus, the formation of a European network that collates scattered knowledge, resources and expertise on gaseous mediators will encourage the dissemination of innovation, boost collaborations and increase the European competitiveness in this field. In the longer term, we anticipate this concerted effort will accelerate translational research in inflammation, cardiovascular disease and CNS disorders, areas in which the biology of these three gaseous molecules has been implicated. The benefits from the support of such a network are expected in multiple levels: scientific, innovation/technological and societal.

Chair
Prof. Andreas PAPAPETROPOULOS
University of Patras Lab for Molecular Pharmacology,
Dept of Pharmacy
26504 Patras Greece
This email address is being protected from spambots. You need JavaScript enabled to view it.

Vice Chair
Dr Adrian HOBBS
William Harvey Heart Centre (1st Floor)
Barts & The London School of Medicine & Dentistry
Charterhouse Square
London EC1M 6BQ
This email address is being protected from spambots. You need JavaScript enabled to view it.

Domain Committee Rapporteur
Dr Maija DAMBROVA
DC Rapporteur of BM1005 BMBS
Latvian Institute of Organic Synthesis Aizkraukles Str. 21 LV1006 Riga Latvia
This email address is being protected from spambots. You need JavaScript enabled to view it.

Science Officer
Dr. Inga Dadeshidze
Senior Science Officer Life Sciences
Science Officer BMBS
COST Office
149 Avenue Louise
1050 Brussels Belgium
This email address is being protected from spambots. You need JavaScript enabled to view it.       

Administrative Officer
Ms Gabriela CRISTEA
COST Office
This email address is being protected from spambots. You need JavaScript enabled to view it.
+32 2 533 38 56

ESF

COST

POLICY STATEMENT: Biomedicine and Molecular Biosciences Action BM1005 is funded by COST, through its implementing agent the European Science Foundation.